Prostate Cancer Clinical Trial

NAVAH Impact on Radiation Therapy Completion in Black Breast & Prostate Cancer Patients

Summary

African-Americans have disparately limited access to optimal cancer care. They have the highest overall cancer death rate and shortest survival time of any racial or ethnic group in the United States. Elucidation of disparities in access to cancer care are important since previous work has indicated that when equal access to RT in Radiation Therapy Oncology Group (RTOG) prospective randomized trials is granted, race does not independently affect outcomes, a finding similar to work conducted in Level I evidence-proven optimal management of curable neurologic conditions. Breast cancer is the most common cancer in African-American women and Prostate cancer is the most common cancer in African-American men. African-American breast & prostate cancer participants are less likely to receive standard-of-care radiation therapy.

Previous work has identified that compared to Caucasian women with breast cancer, African-American women are 48% more likely to have RT omission during treatment, 167% less likely to receive timely completion of RT after breast-conserving surgery, 40% less likely to complete RT, and significantly more likely to experience RT treatment delays. Shorter course radiation therapy may reduce disparities in radiation therapy care facing African-American breast cancer participants.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Subjects must have histologically or cytologically confirmed Breast or Prostate Cancer.
Subjects must be Age >18 years. This study requires informed consent by the subject; as children are not able to perform this without parental approval, subjects < age 18 are excluded from this study.
Subjects must be of African - American race.
Subjects must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

Subjects NOT of African - American ethnicity.
Subjects WITHOUT histologically or cytologically confirmed Breast or Prostate Cancer.

Study is for people with:

Prostate Cancer

Estimated Enrollment:

200

Study ID:

NCT05978232

Recruitment Status:

Not yet recruiting

Sponsor:

Case Comprehensive Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Cleveland Ohio, 44106, United States More Info
Shearwood McClelland III, MD
Contact
216-702-8700
[email protected]
Shearwood McClelland III, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Estimated Enrollment:

200

Study ID:

NCT05978232

Recruitment Status:

Not yet recruiting

Sponsor:


Case Comprehensive Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.